---
title: "Roth MKM Reaffirms Their Buy Rating on Coya Therapeutics, Inc. (COYA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291760677.md"
description: "Roth MKM analyst Boobalan Pachaiyappan reaffirmed a Buy rating on Coya Therapeutics (COYA) with a $12.00 price target. While the broader market consensus for COYA is Strong Buy with an average target of $15.25, Pachaiyappan maintains his specific valuation. He covers the Healthcare sector and has a historical success rate of 46.41% on recommended stocks."
datetime: "2026-07-06T06:05:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291760677.md)
  - [en](https://longbridge.com/en/news/291760677.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291760677.md)
generator: "portal-rs"
---

# Roth MKM Reaffirms Their Buy Rating on Coya Therapeutics, Inc. (COYA)

In a report released today, Boobalan Pachaiyappan from Roth MKM maintained a Buy rating on Coya Therapeutics, Inc., with a price target of $12.00.

### 4th of July Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Pachaiyappan covers the Healthcare sector, focusing on stocks such as Capricor Therapeutics, CervoMed, and PolyPid. According to TipRanks, Pachaiyappan has an average return of 2.0% and a 46.41% success rate on recommended stocks. 

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Coya Therapeutics, Inc. with a $15.25 average price target.

### Related Stocks

- [COYA.US](https://longbridge.com/en/quote/COYA.US.md)
- [CAPR.US](https://longbridge.com/en/quote/CAPR.US.md)
- [CRVO.US](https://longbridge.com/en/quote/CRVO.US.md)
- [PYPD.US](https://longbridge.com/en/quote/PYPD.US.md)

## Related News & Research

- [Roth MKM Sticks to Its Buy Rating for Coya Therapeutics, Inc. (COYA)](https://longbridge.com/en/news/296711581.md)
- [Coya Therapeutics, Inc. (COYA) Gets a Buy from Lake Street](https://longbridge.com/en/news/286280716.md)
- [Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Spyre Therapeutics (SYRE)](https://longbridge.com/en/news/297408646.md)
- [Alliance Global Partners Reaffirms Their Buy Rating on Pelthos Therapeutics (PTHS)](https://longbridge.com/en/news/296781912.md)
- [Spero Therapeutics files $300M mixed securities shelf](https://longbridge.com/en/news/297380989.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**